Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anamaria Manea

Pediatric Endocrinology Reno, NV Medical Doctor

NPI 1770843856 CMS profile 869197

75 Pringle Way Ste 909, Reno, NV 89502

Open in the dashboard

General payments

$23,336

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anamaria Manea of Reno, NV is reported in the CMS Open Payments database as having received $23,336 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,903 45
2024 General $965 5
2023 General $137 1
2022 General $134 14
2020 General $24 1
2019 General $171 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anamaria Manea
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Anamaria Manea were reported at $21,903. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Anamaria Manea Pediatric Endocrinology median Middle half National median
2019 $171 $196 $68–$845 $163
2020 $24 $124 $37–$722 $114
2021 $0 $134 $35–$691 $132
2022 $134 $177 $47–$726 $149
2023 $137 $236 $75–$887 $160
2024 $965 $259 $91–$979 $164
2025 $21,903 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $13,315 21 payments
  2. Kyowa Kirin, Inc. $7,325 14 payments
  3. Eton Pharmaceuticals, Inc. $1,000 1 payment
  4. AstraZeneca Pharmaceuticals LP $725 1 payment
  5. Alexion Pharmaceuticals, Inc. $171 4 payments
  6. Insulet Corporation $138 6 payments
  7. Sanofi-Aventis U.S. LLC $138 2 payments
  8. Ascensia Diabetes Care US Inc. $137 1 payment
  9. Abbott Laboratories $134 14 payments
  10. Novo Nordisk Inc $134 3 payments
  11. Other $119 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $9,975 3 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,595 3 payments
  3. Food and Beverage $1,959 50 payments
  4. Travel and Lodging $1,657 11 payments
  5. Education $150 3 payments
Products named General payments · program years 2019–2025
  1. CRENESSITY $13,315 21 payments
  2. CRYSVITA $7,325 14 payments
  3. Alkindi $1,000 1 payment
  4. KHINDIVI $1,000 1 payment
  5. INCRELEX $1,000 1 payment
  6. STRENSIQ $725 1 payment
  7. Omnipod $138 6 payments
  8. TZIELD $138 2 payments
  9. Sogroya $134 3 payments
  10. FreeStyle Libre 2 $86 9 payments
  11. Other $214 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record